Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI ranks Biomerica Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Biomerica Inc is a small-cap company with a market capitalization of $8M. It ranks number 13 by market capitalization among the 15 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its Gross Margin of 4.1% is the lowest of the 9 peers that report one.
A per-ticker accuracy statistic for BMRA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BMRA included.
Follow BMRA free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
| Metric | BMRA | Rank |
|---|---|---|
| Market Cap | $8M | 13/15 |
| P/B Ratio | 2.55x | 6/11 |
| EPS | $-2.12 | – |
| Book Value/Share | $0.72 | – |
| Metric | BMRA | Rank |
|---|---|---|
| Gross Margin | 4.1% | 9/9 |
| Operating Margin | -117.3% | 8/14 |
| EBT Margin | -91.0% | 8/14 |
| Tax Rate | -0.5% | – |
| Metric | BMRA | Rank |
|---|---|---|
| D/E Ratio | 0.47x | 8/12 |
| Financial Leverage | 1.47x | 8/12 |
| Interest Coverage | -7344.2x | 14/14 |
| Metric | BMRA | Rank |
|---|---|---|
| Operating Cash Flow | -$3M | 6/16 |
| Metric | BMRA | Rank |
|---|---|---|
| Operating Income | -$5M | 4/15 |
| R&D Expense | $830K | 15/16 |
| SG&A Expense | $5M | 12/12 |
| Cost of Goods Sold | $4M | 8/10 |
| Metric | BMRA | Rank |
|---|---|---|
| Shares Outstanding | 5M | – |
| EPS Growth | -115.2% | – |
| Total Liabilities | $2M | 32.0% of assets |
Companies classified under the same SEC industry code as Biomerica Inc (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| BMRA Biomerica Inc | ▲ | $8M |
| IDXX Idexx Laboratories Inc /De | ▼ | $40.99B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.53B |
| NEOG Neogen Corp | ▲ | $2.56B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.22B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.67B |
| QDEL Quidelortho Corp | ▶ | $967M |
| ACHV Achieve Life Sciences, Inc. | ▶ | $720M |
| TKNO Alpha Teknova, Inc. | ▲ | $441M |
| MYGN Myriad Genetics Inc | ▲ | $390M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▲ | $87M |
| AWHL Aspira Women's Health Inc. | ▲ | $12M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▶ | $5M |
| VNRX Volitionrx Ltd | ▼ | $3M |
| QCLS Q/C Technologies, Inc. | ▼ | N/A |
| TRIB Trinity Biotech Plc | ▼ | N/A |
Biomerica, Inc. announced that the American Medical Association's CPT editorial panel has granted a Proprietary Laboratory Analysis (PLA) code for its inFoods® IBS test, which personalizes the ...
IRVINE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a developer and manufacturer of diagnostic test systems and CDMO services provider, today announced it has entered into ...
IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) ("Biomerica"), a global provider of advanced medical products, today announced that it will implement a 1-for-8 ...
Our AI ranks Biomerica Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
A per-ticker accuracy statistic for BMRA is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Biomerica Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
17 issuers in our coverage, BMRA included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.